Genotype-guided warfarin dosing algorithms are a rational approach to optimize warfarin dosing and potentially reduce adverse drug events. Diverse populations, such as African Americans and Latinos, have greater variability in warfarin dose requirements and are at greater risk for experiencing warfarinrelated adverse events compared with individuals of European ancestry. Although these data suggest that patients of diverse populations may benefit from improved warfarin dose estimation, the vast majority of literature on genotype-guided warfarin dosing, including data from prospective randomized trials, is in populations of European ancestry. Despite differing frequencies of variants by race/ethnicity, most evidence in diverse populations evaluates variants that are most common in populations of European ancestry. Algorithms that do not include variants important across race/ethnic groups are unlikely to benefit diverse populations. In some race/ethnic groups, development of race-specific or admixture-based algorithms may facilitate improved genotype-guided warfarin dosing algorithms above and beyond that seen in individuals of European ancestry. These observations should be considered in the interpretation of literature evaluating the clinical utility of genotype-guided warfarin dosing. Careful consideration of race/ethnicity and additional evidence focused on improving warfarin dosing algorithms across race/ethnic groups will be necessary for successful clinical implementation of warfarin pharmacogenomics. The evidence for warfarin pharmacogenomics has a broad significance for pharmacogenomic testing, emphasizing the consideration of race/ethnicity in discovery of gene-drug pairs and development of clinical recommendations for pharmacogenetic testing.
and dose variability have led to the development of dose prediction algorithms to facilitate attainment of optimal anticoagulation. Such dose prediction algorithms incorporate factors such as age, weight, race/ethnicity, drug interactions, and target international normalized ratio (INR). These algorithms are improved by the incorporation of genetic variants affecting warfarin dose, which led to refinement of these algorithms and updates in the U.S. Food and Drug Administration (FDA)-approved warfarin labeling. 8, 9 More than 30 genotype-guided warfarin dosing algorithms have been published for warfarin and other coumarin anticoagulants. 10 However, uptake of these algorithms into clinical practice has been slow, with few clinical guidelines supporting use of pharmacogenetic testing. 11 Average daily warfarin doses differ by race/ ethnicity. For example, the daily dose needed to reach a stable therapeutic INR is estimated at 5.1 mg in individuals of European ancestry, 5.7 mg in individuals of African ancestry, 4.4 mg in Latinos, 3.4 mg in individuals of Asian ancestry, and 4.5 mg in American Indian/ Alaska Natives (AI/ANs). [12] [13] [14] Diverse populations, such as African Americans (AAs) and Latinos, are significantly underrepresented in studies that developed clinical and genotype-guided dosing algorithms. 15, 16 This underrepresentation, combined with the results of several studies, have cast doubt on the utility of pharmacogenetic testing to estimate warfarin dose, especially in diverse populations. [17] [18] [19] This is particularly concerning given that these populations may have the most to gain from efforts to improve warfarin management. Warfarin dose variability appears to be greatest in populations that are not of European ancestry. 20 In addition, Latinos and AAs are at greater risk for poor outcomes, particularly warfarin-related intracranial hemorrhage, as a result of suboptimal warfarin management. 21, 22 We review existing evidence for variants that affect warfarin dose requirements and the performance of genotype-guided dosing algorithms. We present detailed data on studies in diverse populations, focusing on key minority populations, in order to summarize the inclusion of race/ethnic groups, frequency of genetic variants, and performance of genotype-guided dosing algorithms by race/ethnicity. Finally, we offer perspectives on the future direction of warfarin pharmacogenetic research and potential implications for clinical practice.
Warfarin Pharmacogenomics in Individuals of European Ancestry
Single nucleotide polymorphisms (SNPs) in genes encoding proteins involved in warfarin pharmacokinetic and pharmacodynamic pathways have been associated with warfarin dose requirements ( Figure 1) . 23, 24 Cytochrome P450 family 2 subfamily C member 9 (CYP2C9) is the enzyme primarily responsible for metabolizing the more potent S-enantiomer of warfarin to an inactive metabolite. Multiple SNPs in the gene CYP2C9 alter the amino acid sequence and thus confer reduced enzyme function and decreased warfarin metabolism. Warfarin elicits its anticoagulant effect by inhibiting vitamin K epoxide reductase (VKORC1), the enzyme responsible in activating downstream clotting factors. 24 An SNP in CYP4F2, which plays a role in catalyzing free vitamin K to hydroxyvitamin K, increases warfarin dose requirements. 25 Other genes with variation affecting warfarin dose include calumenin (CALU), 26 which functions as a chaperone for c-glutamyl carboxylation, c-glutamyl carboxylase (GGCX), 27 which contributes to activating clotting factors, and NAD(P)H quinone dehydrogenase 1 (NQO1), 28 which helps reduce vitamin K to vitamin K hydroquinone, the activating cofactor for c-glutamyl carboxylase.
In individuals of European ancestry, variants in CYP2C9, VKORC1, and CYP4F2 explain an estimated 9%, 25%, and 2% of the variability in warfarin dose requirements, respectively. 9, 20, 29 In response to the mounting evidence of the impact of CYP2C9 and VKORC1 SNPs on warfarin dose requirements, the FDA updated the warfarin dosing label in 2010. 8 This label includes a table of initial dosing recommendations based on CYP2C9 and VKORC1 genotypes. Although simple to implement clinically, the table ignores many of the other clinical factors affecting warfarin dose requirements, such as age, weight, drug interactions, and INR. Among the most commonly used algorithms to predict stable warfarin dose are the Gage algorithm and the International Warfarin Pharmacogenetics Consortium (IWPC) algorithm. 9, 20 These algorithms were developed in populations of primarily European ancestry and consider race/ ethnicity as a variable within the algorithm. The vast majority of warfarin pharmacogenetic studies have been conducted in populations with European ancestry, especially studies that investigate the clinical utility of genotype-guided warfarin dosing (Figure 2 ; Table S1 ). 16 Despite the FDA label change and the availability of these algorithms, uptake of genotypeguided warfarin dosing into clinical practice has been slow. Proponents of warfarin pharmacogenetic testing support incorporation of testing recommendations into clinical guidelines, citing the wealth of evidence supporting improvement of initial warfarin dose estimation using genotype data. 11 The Clinical Pharmacogenetics Implementation Consortium (CPIC) strongly advises using an individual's genotype to guide therapy based on the improved predictability to achieve a stable dose compared with standard care. 11 An important caveat is that CPIC guidelines assume genetic data are available before warfarin initiation. The guidelines do not provide recommendations for when to order pharmacogenetic testing. Opponents of warfarin pharmacogenetic testing cite the lack of supporting data from randomized prospective trials, as well as the cost of genotyping. 30 The American College of Chest Physicians (ACCP) recommends against ordering pharmacogenetic testing to guide warfarin dosing, citing the absence of data showing improvement in patient outcomes, such as bleeding and thrombotic events. 30 However, Figure 1 . Genes involved in warfarin metabolism and mechanism of action. CALU = calumenin; CYP2C18 = cytochrome P450 family 2 subfamily C member 18; CYP2C9 = cytochrome P450 family 2 subfamily C member 9; CYP4F2 = cytochrome P450 family 4 subfamily F member 2; GGCX = gamma-glutamyl carboxylase; NAD = nicotinamide adenine dinucleotide; NQO1 = NAD(P)H quinone dehydrogenase 1; VKORC1 = vitamin K epoxide reductase. Table S1 . AA = African American.
ACCP's guideline did not address whether pharmacogenetic information should be used if available at the time of warfarin initiation. The results of three randomized controlled trials (RCTs) demonstrated different results regarding the clinical utility of warfarin pharmacogenetic testing. [17] [18] [19] The results of these three RCTs are summarized in Table S2 . The only trial to observe a benefit used a fixed dose approach as a comparator. The European Pharmacogenetics of Anti-coagulant Therapy (EU-PACT) group recruited 454 patients and found a significant improvement in the percentage of time patients were able to maintain a stable warfarin dose when initial dosing predictions were based on genotype-guided dosing versus fixed-dosing (67.4% vs 60.3% time in therapeutic range [TTR], p<0.001). 18 Although a fixed-dose approach may be more representative of clinical practice, it is unclear whether the pharmacogenetic data or the clinical data used to predict dose were driving the observed benefit. Conversely, the Clarification of Optimal Anticoagulation through Genetics (COAG) study in 955 patients found no improvement in TTR when patients received predicted warfarin dosing based on genotype-guided methods compared with dosing based solely on clinical factors (45.2% vs 45.4% TTR, p=0.91). 17 The results of COAG suggest that a clinically guided algorithm is sufficient for improvement in dosing estimation.
A second EU-PACT study evaluated TTR for a genotype-guided algorithm and a clinical algorithm for dosing the warfarin derivatives acenocoumarol and phenprocoumon. 19 This study observed no significant improvement in percent TTR in the genotype-guided group compared with patients receiving clinically guided dosing (61.6% vs 60.2%, p=0.52) ( Table S2 ). The interpretation and generalizability of these trials are complicated by discordant study designs, including differences in comparator groups, total number of patients, follow-up time, warfarin loading dose, time of dose initiation, time of INR measurement, and time of genotype availability. In addition, these three trials used a surrogate marker, TTR, as a primary outcome rather than clinical outcomes, such as bleeding or thromboembolic events, thus limiting interpretability in terms of clinical utility.
A possible explanation for the disparate results of these trials is the distribution of race/ethnicity. The EU-PACT and COAG trials used the IWPC and Gage algorithms, which were derived from individuals of primarily European ancestry and include the variants CYP2C9*2, CYP2C9*3, and VCORC1-1639G>A. [17] [18] [19] Although EU-PACT consisted of a patient cohort with 98.5% selfreported European ancestry, the COAG trial was composed of a more-diverse cohort with 27% AA patients. [17] [18] [19] In COAG, variability in warfarin dose explained by the genotype-guided algorithm was 52% in individuals of European ancestry and as low as 17% in AAs. 31 The AAs who were assigned to the genotype-guided arm had a significantly lower TTR than those in the clinically guided arm (35.2% vs 43.5%, p=0.0003) ( Table S2) . 17 These findings suggest that European-based genetic algorithms do not accurately predict warfarin dose in AAs, and the same concern exists for other under-represented populations of non-European ancestry.
Identification of Warfarin Pharmacogenomic Variants in Diverse Populations
Diverse populations encounter greater adverse health risks during warfarin therapy compared with European patients. Asians, Latinos, and AAs are at greater risk of warfarinrelated intracranial hemorrhage outcomes than individuals of European ancestry. 22 In addition, AAs, Latinos, Asians, and Native Americans have significant reductions in TTR compared with individuals of European ancestry. An assessment of warfarin management showed individuals of African and Hispanic ancestry had lower median TTR than individuals of European ancestry (59% vs 62% vs 68%, p<0.0001). 21 A similar study found lower mean TTRs in AAs, Asians, and Native Americans combined compared with European patients. 32 These observations suggest that diverse populations stand to benefit from more-accurate dose estimation provided by genotype-guided warfarin dosing.
Differences in the frequencies of warfarin pharmacogenetic variants partially explain the early clinical observations of different warfarin dose requirements by race/ethnicity. For instance, the VKORC1-1639G>A allele is less common in individuals with African ancestry, partially accounting for higher warfarin dose requirements in AAs (Table 1) . 33, 34 The CYP2C9*2 and *3 alleles are more prevalent in individuals of European ancestry, whereas the CYP2C9*8 and *11 alleles are more prevalent in AAs. These differences in minor allele frequency (MAF) are compounded by the existence of race-specific variants that contribute to warfarin dose variability. If important functional variants are not recognized or identified for a given race/ ethnic group, the clinical utility of genotypeguided algorithms is limited. Literature identifying these variants and their frequencies is summarized below.
Individuals of African Ancestry
The majority of warfarin pharmacogenetic studies in individuals of African ancestry have been performed in AA populations from the United States.
15, 28, 35-37 CYP2C9*2 and CYP2C9*3 are not as useful in predicting warfarin dose requirements in AAs, partly because of their lower prevalence compared with individuals of European ancestry. 38 Important warfarin pharmacogenetic variants in AAs include CYP2C9*5,*6,*8,*11, and 18786T, rs12777823 in the CYP2C gene cluster, VKORC1-1639G>A, GGCX (CAA) 16/17, and CALU rs339097 ( Table 1) . Most of these variants have increased MAFs in AAs compared with individuals of European ancestry, with the exception of VKORC1-1639G>A. For example, the MAF of the CALU rs339097 is less than 1% in Europeans but 9-14% in AAs, and corresponds to an 11% to 15% higher warfarin dose requirement in AAs.
34, 39 CYP4F2*3 and NQO1*2 have lower MAFs compared with populations of European ancestry and do not account for significant warfarin dose variability in AAs. 28 The presence of the GGCX (CAA) 16/17 repeat polymorphism, which accounts for 2% of warfarin dose variability, is 10 times more common in AAs than in populations of European ancestry. 40 In a targeted resequencing study of AAs, new variants affecting warfarin dose were found in both VKORC1 and CYP2C9. 34 The presence of VKORC1-8191 and CYP2C9 18786T resulted in significantly higher warfarin doses and significantly improved warfarin dosing algorithm R 2 , which represents the percentage of variation in warfarin dose explained by the algorithm. A genome-wide association study (GWAS) of warfarin dose variability in AAs also observed a significant association with rs12777823 G>A located near CYP2C18, a variant in a gene previously unknown to affect warfarin dose requirements. 41 Individuals heterozygous for the A allele required 6.92 mg less warfarin per week, and homozygous individuals required 9.34 mg less warfarin per week than those with the GG genotype. The rs12777823 SNP is also common in Europeans but is not associated with warfarin dose in this population, suggesting that it is not functional, but rather inherited with a yet unidentified functional variant. The CYP2C9*5,*6,*8, and *11 alleles occur almost exclusively in populations of African ancestry. 
39
AI/AN = American Indian/Alaska Native; CALU = calumenin; CYP = cytochrome P450; GGCX = c-glutamyl carboxylase; NQO1 = NAD(P)H dehydrogenase,quinone 1; VKORC1 = vitamin K epoxide reductase.
a Minor allele frequencies were obtained from NCBI dbSNP 1000 genomes using super population codes for East Asian, European, African, and admixed American and from researchers. 
Latino Populations
The rich genetic diversity of the Latino population makes generalizations regarding the presence and frequency of variants difficult. The majority of published studies have been performed in either Mexican or Caribbean Latinos. 28, [42] [43] [44] [45] In contrast to AAs, MAFs of variants affecting warfarin dose requirements in Latinos are similar to MAFs in populations of European ancestry (Table 1) . 28, 39 The CYP29*2, CYP2C9*3, and VKORC1-1639G>A variants were shown to account for 56% of the variability observed in warfarin dose requirements in a population of primarily Mexican descent. 46 The variant CYP4F2*3 has also been associated with an increase in warfarin dose requirements in both Mexican and Caribbean Latino populations. 28, 43 In contrast to AAs and populations of European ancestry, NQO1*2 has an increased MAF in Latinos and has been associated with an increase in warfarin dose requirements in this population. The addition of CYP4F2*3 and NQO1*2 explained about 68% of warfarin dose variability in Latinos compared with 58% in algorithms that do not include these variants. 28 
Individuals of Asian Ancestry
Aside from populations of European ancestry, Asian populations, particularly from China, are the best studied with respect to warfarin pharmacogenomics. However, these studies tend to focus on developing new algorithms based on clinical data and known European variants rather than discovery of new variants or clinical utility of genotype-guided algorithms, with some exceptions. 12, 47, 48 In addition, few of these studies have been performed in Asian populations within the United States. The variants identified that are known to significantly influence warfarin dose requirements include CYP2C9*3, VKORC1-1639G>A, and CYP4F2*3. Similar to populations of European ancestry, the total variability in warfarin dose explained by CYP2C9*3, VKORC1-1639G>A, and CYP4F2*3 is estimated at 40-63% in Asian populations. 48 In a Chinese subgroup, total warfarin dose variability explained by CYP2C9*3 was comparable to populations of European ancestry at 11.2%. However, the effect of CYP2C9*2 on warfarin dose is essentially nonexistent in Asian patients at a population level as the MAF is negligible (Table 1) . VKORC1-1639G>A is significantly associated with reduced warfarin dose requirements as AA, GA, and GG genotypes correspond to daily differences in warfarin dose of 3, 5, and 6 mg, respectively. 39 The frequency of the VKORC1-1639G>A allele in Asian populations is substantial (88%) compared with other race/ethnic groups, which partially explains the reduced warfarin dose requirements in Asian patients. 12 Variability in warfarin dose due to VKORC1-1639G>A is estimated at 29% in populations of Asian ancestry. The frequency of CYP4F2*3 and the contribution of CYP4F2*3 to warfarin dose variability in Asian populations are also comparable to those of populations of European ancestry. 48 Recently, variants in the cytochrome P450 oxidoreductase gene (POR) have also been observed to affect warfarin dose requirements in Chinese patients, similar to a study in individuals of European ancestry. 49 American Indian/Alaska Native The AI/AN populations are among the most underrepresented race/ethnic groups in warfarin pharmacogenetic studies. 13, 43 One study observed a correlation between AI ancestry and low warfarin dose requirements, with a higher proportion of AI patients having low-dose requirements (<3 mg/day) compared with the rest of the population (i.e., 33% vs 19%, p<0.01). 43 However, this study was performed in Caribbean Latinos rather than an AI/AN population. Another study identified CYP2C9*2, CYP2C9*3, VKORC1-1639G>A, and CYP4F2*3 as contributors to warfarin dose variability in AI/AN patients. 13 The AI/AN population displayed a high frequency of alleles conferring increased warfarin sensitivity, suggesting a reduction in warfarin dose requirements in this population. Two novel nonsynonymous variants (M1L and N218l) were also identified in the CYP2C9 gene. 13 Although confirmation of the effects of these nonsynonymous mutations is necessary, the presence of novel mutations suggests that additional research aimed at discovery of novel polymorphisms associated with warfarin dose variability is necessary.
Genotype-Guided Warfarin Dosing Algorithms in Diverse Populations
Populations of primarily European ancestry are by far the most well-studied race/ethnic group in terms of warfarin pharmacogenomic testing. Of 12 prospective randomized trials investigating genotype-guided warfarin dosing, individuals of European ancestry accounted for 79.9% of all study populations combined, whereas Latinos accounted for 2%, AAs for 9.5%, and individuals of Asian ancestry for 6.9% (Figure 2 ; Table S1 ). The lack of exhaustive studies in non-European populations raises the fundamental question of whether algorithms developed in European populations can be generalized to more-diverse populations. Algorithms that were developed in populations of European ancestry may miss important variants in other race/ethnic groups. In addition, variants may have differing effects depending on the race/ethnic group, resulting in use of incorrect effect sizes and incorrect dose estimates. 15 In the next section, we summarize literature evaluating the performance of European-derived warfarin pharmacogenetic algorithms and the development of race-specific algorithms in diverse populations.
Individuals of African Ancestry
Several studies have tested the performance of genotype-guided warfarin dosing algorithms in AAs ( Table S3 ). Studies that genotype polymorphisms from populations of European ancestry explain a relatively low amount of variance observed in AA patients compared with individuals of European ancestry. 50 This observation is consistent with the results of the COAG trial, which used a European-derived algorithm and observed reduced TTR, as well as an increase in adverse outcomes in AAs (Table S2) . 17 Subsequent studies developed AA-specific algorithms that incorporate variants with warfarin dose effects in AAs, such as CYP2C9*5, *6, *8, and *11 and rs12777823. Such studies observed improvements in performance (R 2 = 38%) versus traditional genotype-guided algorithms, such as the IWPC (R 2 = 26%) ( Table 2) . 35 In a retrospective analysis using electronic health records, clinical information alone explained 24% of variation in stable dose in AAs, the IWPC algorithm improved R 2 to 29%, and an expanded genetic algorithm, including CYP2C9*6, CYP2C9*8, CYP4F2*3, and CALU rs339097, improved the R 2 to 41%. 37 Similar results were observed in other studies, in which AA-specific algorithms explain more of the phenotypic variation (R 2 = 27%) than IWPC (R 2 = 15%) or clinical (R 2 = 16%) algorithms. 15, 57 Interestingly, a significant inverse correlation between predicted dose and percent West African ancestry was observed for the IWPC pharmacogenomics algorithm among patients requiring ≥ 60 mg/week (b = À2.04, p=0.02). 36 Taken together, these results suggest that incorporation of AA-specific variants facilitate improvements in prediction of warfarin dose variability in individuals of African ancestry. This constitutes strong evidence that algorithms derived from predominately European populations cannot be broadly applied to AAs. In fact, such algorithms may perform worse than clinical algorithms in AAs. 15, 17 Available data in AAs support a race-stratified approach if genotype-guided warfarin dosing algorithms are to be used. Recently, a race-stratified approach to genotype-guided dosing in AAs was recommended in updated warfarin CPIC guidelines. 11 However, despite the availability of new AAderived algorithms, predicted variability in warfarin dose remains low relative to populations of European ancestry. This suggests that genotype-guided dosing will not have as much clinical utility in AAs as in individuals of European ancestry in the absence of identifying and incorporating additional variants influencing dose in AAs. Nevertheless, these data highlight the limited number of prospective randomized trials evaluating variants from AAs in genotypeguided warfarin dosing algorithms.
Latino Populations
The majority of the evidence evaluating genotype-guided warfarin dosing algorithms in Latinos has been performed in either Brazilian or Puerto Rican populations. Few studies have been performed in individuals of Mexican ancestry. Available evidence in Brazilian populations suggests that European-derived dosing algorithms including CYP2C9*2, CYP2C9*3, and VKORC1-1639G>A perform reasonably well (R 2 = 40-51%) (Table S4) . 45, 58 A genotype-guided algorithm developed in Brazilian patients with a high percentage of European ancestry more accurately explained warfarin dose variability in this population than the IWPC algorithm (R 2 = 63% vs R 2 = 46%) ( Table 2) . 51 In Puerto Rican populations, the warfarin dose variability predicted using European-derived dosing algorithms is substantially higher (R 2 = 67%) (Table S4) . 44 A tailored algorithm for Puerto Rican patients also performed better than the IWPC algorithm (R 2 = 67% vs R 2 = 36%) ( Table 2) . 44 Overall, these novel algorithms Algorithms studied were developed in the study cited unless otherwise specified. If multiple algorithms were compared in the reference study, the best performing algorithm is included in the developed for subpopulations of Latino populations predicted the warfarin dose more accurately than the IWPC algorithm. However, these algorithms are being tested in the same populations in which they are developed, which likely increases R 2 values, and these algorithms use different clinical variables than IWPC.
An admixture-based approach to genotypeguided warfarin dosing has also been developed. 43 Latino populations are characterized by a large amount of admixture, which can be defined as interbreeding between two or more previously isolated populations, and an admixture-based approach is uniquely suited to their genetic diversity. In this study, an admixture index was calculated based on STRUCTURE-defined race (1 = European ancestry, 2 = Native American ancestry, 3 = African ancestry, 4 = admixed individual). This admixture vector explained approximately 6% of the variance in effective warfarin dose requirements after taking into account the contribution of other covariates. In contrast to a race-specific algorithm, this approach accommodates for the fact that many race/ethnic groups will not fit neatly into an ancestral population. The approach may have broader implications for other race/ethnic groups moving forward and could bolster use of other estimates of admixture to be used, such as percent ancestry and principal components analysis.
Individuals of Asian Ancestry
A relatively large number of studies that evaluated the performance of genotype-guided warfarin dosing algorithms in populations of Asian ancestry have been published (Table S5) . [53] [54] [55] [56] [59] [60] [61] [62] These studies were conducted primarily in individuals from China, Korea, and Japan, with virtually no studies from Asian populations within the United States. Such studies focus heavily on variants associated with warfarin response from European populations, such as CYP2C9*3 (CYP2C9*2 has a negligible frequency in Asians populations) and VKORC1-1639G>A. Performance of genotype-guided dosing algorithms from these studies is comparable to the performance of the same algorithms in individuals of European ancestry, with R 2 ranging from 33% to 70% (Table S5) .
Multiple studies have evaluated the performance of algorithms developed in individuals of Asian ancestry versus traditional pharmacogenetic algorithms (Table 2) . [52] [53] [54] [55] [56] Algorithms developed in populations of Asian ancestry perform comparably to or slightly better than Gage and/or IWPC algorithms, as indicated by R 2 . This result is consistent with population similarity in terms of allele frequencies in individuals of European ancestry. As with the literature relevant to Latinos, these algorithms are often tested in the same population in which they were developed, which likely increases algorithm performance. Further, these algorithms use different clinical variables than traditional dosing algorithms.
Although individuals with Asian ancestry are well studied compared with other diverse populations, the body of evidence underscores the lack of consideration of variants outside traditional genotype-guided dosing algorithms. [52] [53] [54] [55] [56] Individuals from China, Korea, and Japan are unlikely to capture genomic variability across Asian populations with greater African and European ancestry, which is likely to be present in the United States. Therefore, it will be important to consider the diversity of other Asian populations when determining whether and which genotype algorithms should be used clinically.
Summary Observations and Limitations in the Evidence
Whereas variants tend to have similar effects on warfarin dose requirements across race/ethnic groups, differences in the frequency of these variants by race/ethnicity may drive differences in the contribution of these variants to warfarin dose variability. 15, 41 For some populations, such as populations of Asian ancestry, variants identified in populations of European ancestry may capture the majority of variance in warfarin dose. However, novel variants affecting warfarin dose have been identified in AAs, Latinos, and AI/AN groups, suggesting that variants identified in populations of European ancestry may not capture sufficient contributions to warfarin dose variability across diverse populations. This suggests that inclusion of these novel variants in genotype-guided algorithms may be important to improve the predictability of warfarin dose in diverse race/ethnic groups.
The majority of studies in diverse race/ethnic groups have sought to replicate associations of known variants rather than identify new variants. Moving forward, research aimed at discovery of novel polymorphisms affecting warfarin dose variability will likely be necessary if genotype-guided dosing is implemented in these populations. Such studies would need to perform sequencing and/or GWAS rather than SNP genotyping and would thus incur greater costs to discover novel associations. Furthermore, the vast genomic diversity across the United States and the world will likely require repeated efforts for discovery of novel polymorphisms. 63 Because of smaller sample sizes in studies of diverse race/ethnic groups, variants with small but significant effects on warfarin response may go undiscovered.
Multiple studies have been performed to improve the accuracy of genotype-guided warfarin dosing algorithms in minority populations. However, these studies typically evaluate clinical and genetic factors derived from populations of European ancestry rather than discovering new variants among diverse race/ethnic groups. Although the evidence suggests that this approach may be reasonable in Asian populations and, to a lesser extent, Latino populations, this approach leads to inaccurate dosing estimation in AAs. 17 Although variants have been discovered in AI/AN populations, no algorithms have been developed or tested in this population. 13 Additional studies are needed to define important variants and refine genotype-guided algorithms for other minority groups. Definitions of race will be particularly important if these algorithms are to be implemented in morediverse populations. Although these studies provide useful examples, the populations studied are unlikely to capture the majority of worldwide genetic variability across race/ethnic groups. Many of these algorithms were developed in small populations, and some have not been validated in independent populations. The algorithms are often inconsistent with respect to clinical variables used and how performance is measured (e.g., mean absolute error vs R 2 ).
Future Directions
Despite increasing use of DOACs, warfarin is likely to remain an important oral anticoagulant. Some socioeconomic populations may have access barriers to DOACs, and a number of clinical concerns, such as FDA-approved indications, concerns about bleeding risk, contraindication in valvular heart disease, and availability/ expense of an antidote in the event of overdose, may limit DOAC use. If warfarin remains heavily used in clinical practice, improving dosing accuracy should remain a priority, considering the high contribution of the drug to adverse events. 3, 64 Whether improved dosing accuracy is accomplished using clinical algorithms, genotypeguided dosing algorithms, or some other method, consideration of race/ethnicity will be critical considering the increased dose variability and adverse event rates in minority populations. [20] [21] [22] Selection of Genotype-Guided Warfarin Dosing Algorithms in Diverse Populations Race and ethnicity are key considerations in any genetic study, and pharmacogenomics is no exception. Previously, many studies have intentionally excluded diverse race/ethnic groups to eliminate the possibility of population stratification. 16 This highlights one potential reason for the limited evidence in non-European race/ethnic groups. A recent analysis of GWAS studies that were conducted between 2009 and 2016 showed that European populations continue to account for a significant proportion of new studies (>80%), whereas other populations, including AAs, Latinos, and Native Americans, have remained relatively stagnant or decreased in proportion. 65 Research in other race/ethnic groups may be seen as unoriginal or redundant. Other disadvantages of performing these studies is the expense associated with capturing genomic variability in many race/ethnic minorities, who may require the use of specially designed platforms and/or be highly admixed.
Genotype-guided warfarin dosing provides a case study that has broader significance across pharmacogenomics. Moving forward, any implementation of genotype-guided warfarin dosing algorithms is likely to require adequate consideration of race/ethnicity. As the evidence for many drug-gene pairs is primarily within individuals of European ancestry, more studies are needed to identify the effects of existing variants or new variants in diverse race/ethnic groups. It may be reasonable to use European-derived algorithms for some populations, but this approach is unlikely to be valid in other populations. To maximize the utility of pharmacogenomics, it is likely that separate algorithms will need to be developed for many race/ethnic groups. Recent data from population pharmacokinetic modelling support this notion. 66 The updated CPIC guidelines for genotypeguided warfarin dosing incorporate substantial changes based on African ancestry.
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For patients with African ancestry, CPIC now recommends a 15-30% warfarin dose reduction if a patients carries CYP2C9*5, *6, *8, or *11 alleles and recommends against using genotype-guided dosing if these alleles are not captured. If patients are AA, referring to individuals mainly originating from West Africa, the new guidelines recommend a 10-25% dose reduction in rs12777823 A carriers. All patients of non-African ancestry are treated using the European-derived algorithms from previous CPIC guidelines, with optional reductions in dose for patients with CYP2C9*5, *6, *8, or *11 alleles and for CYP4F2 rs2108622 T carriers. The new CPIC guidelines thereby support the use of different algorithms based on African ancestry, where the evidence is strongest, but treat European, Asian, Hispanic, and AI/AN patients by using the same algorithm. Interestingly, the guidelines support the exclusion of classic CYP2C9 and VKORC1 variant data in patients with African ancestry if CYP2C9*5, *6, *8, or *11 alleles have not been genotyped.
Whether a new algorithm needs to be developed for subsets of ancestral populations remains unclear. Admixture within an individual patient should be considered, especially in U.S. populations. Admixture mapping may be required for selection of appropriate algorithms, or for inclusion of an admixture variable. It is unlikely that an accurate algorithm could be developed for each nationality or individual race/ethnic group. The consideration of admixture will be particularly important for U.S. populations, and some progress has been made in developing these models. 43 Additional computational approaches to warfarin dosing, such as machine learning and artificial neural networks, have also been investigated. 67, 68 Although this review focused on U.S. populations, many quality studies have been published evaluating other race/ethnic groups across the globe. 51, 61 These studies can inform research in U.S. populations and can ultimately provide guidance on the best process for accurately predicting warfarin dose.
Clinical Implementation of Genotype-Guided Warfarin Dosing Algorithms A central consideration for the future direction of warfarin dosing algorithms is whether clinical implementation is justified by the present level of evidence. Recommendations are now available for clinical translation of genotypes and, indeed, the FDA has changed the labelling of warfarin to accommodate genotype data. 8, 11 However, seminal clinical guidelines for cardiovascular care have yet to embrace warfarin pharmacogenomics, citing a lack of established efficacy in RCTs and a lack of proven effect on clinical outcomes. 30 Clinical guidelines have readily incorporated pharmacogenomic testing when supported by a randomized trial, as with abacavir for patients with human immunodeficiency virus. 69 The limited clinical utility of pharmacogenetic testing observed in RCTs performed in individuals of European ancestry may not be generalizable to other race/ethnic groups. Based on the poor performance of genotype-guided algorithms in AAs, additional randomized trials may be needed in AAs and potentially other race/ethnic groups.
Thus, a key issue in implementation is the threshold of evidence at which pharmacogenomics testing should be incorporated in the clinic. Some groups maintain that RCTs should not be required because a new drug entity is not being approved. These groups cite the incorporation of renal dose adjustments in clinical care and a slew of other clinical adjustments that are not supported by RCTs. An RCT for personalized medicine can be seen as a contradiction in terms, in that a randomized treatment structure is applied to personalized care. 70 Opponents of this view maintain the central requirement of RCT level evidence in clinical decision making.
Pharmacoeconomic Considerations
One may argue that a pharmacoeconomic threshold of evidence should be instituted. That is, since a new drug is not being approved, financial justification for genetic testing should be the point at which the testing is incorporated into practice. This approach is indirectly supported by CPIC guidelines, which recommend using pharmacogenomic data when it is available rather than order genetic testing each time a new warfarin prescription is ordered, essentially avoiding concerns regarding cost-effectiveness. 71 This is a reasonable approach, considering that no additional cost is incurred for testing, yet data are still used to improve dosing recommendations. Although there will be relatively few patients with these data today, the number is increasing with increasing clinical and direct-toconsumer testing. This approach has the caveat that it introduces additional problems of consistency of reporting and interpretability of results.
Earlier cost-effective analysis studies performed from 2009-2010 suggest that warfarin pharmacogenetic testing improved qualityadjusted life-years (QALYs) gained but not at a cost-effective level. [72] [73] [74] [75] For the majority of economic studies, the accepted threshold at which a test or intervention is deemed costeffective is $50,000/QALY gained. 76 The calculated cost-effectiveness ratios in the studies ranged from $50,000/QALY gained to above $170,000/QALY gained, with costs most influenced by the price of genetic testing, the clinical outcome, the time to receive genetic testing results, and the propensity of high-risk patients to bleed or clot during warfarin therapy. Costeffectiveness could be met if genotype-guided dosing methods improved the TTR by 5% to 9%, reduced the risk of major bleeding by 32%, improved warfarin management for high-risk patients, reduced genetic testing availability to within 24 hours, and the cost of genetic testing fell to under $200. 73, 74 Pharmacoeconomic studies have suggested a growing improvement in cost-effectiveness. A meta-analysis of major RCTs comparing pharmacogenetic guided dosing to standard dosing showed an improvement of TTR by 6% and a reduction in the risk of major bleeding by 66%. 77 The European Pharmacogenetics of Anticoagulant Therapy, an ongoing RCT, uses a bedside test that can provide results to guide therapy within 1.5 hours. 78 In addition, the cost of genetic testing continues to fall. For example, prices for warfarin genotyping ranged from $400 to $550 in 2009 and from $25 to $200 beginning in 2013. 74, 79 Two simulation trials that incorporated these updated factors showed that genetic testing before warfarin initiation therapy can be highly cost-effective, falling below the accepted $50,000/QALY gained threshold compared with standard warfarin dosing. 76, 80 As technology moves forward and genotyping becomes less costly and more accurate, one would expect genomic data to be available on the majority of patients as standard of care. This would make genotyping for pharmacogenomics variants, as well as ancestry markers, unnecessary, and potentially facilitate implementation into clinical care. Until genomic sequencing is commonplace within the clinic, pharmacogenomic implementation might be considered premature. Nevertheless, research into the influence of variants on drug response will inform clinical practice as genomic data become available in the majority of patients.
Conclusions
The vast majority of published literature on genotype-guided warfarin dosing is derived from populations of European ancestry. In addition, the vast majority of evidence in more diverse populations evaluates genetic variation from populations of European ancestry. However, the frequency and effect of variants may differ based on race/ethnicity, and additional studies in diverse populations are needed if pharmacogenetic testing is carried out in these groups. In some race/ethnic groups, development of racespecific or admixture-based algorithms may facilitate improved safety and efficacy of warfarin above and beyond that seen in individuals of European ancestry. Finally, the evidence with warfarin pharmacogenomics may have a broader significance on pharmacogenomic testing, emphasizing the consideration of race/ethnicity in discovery of gene-drug pairs and development of guidelines. Ensuring broad benefit from genotype-guided warfarin dosing is contingent on accounting for genotypes that are important across populations.
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